- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.04. | Cline Scientific provides an update on the company's financial position | 1 | Cision News | ||
| 23.02. | Bokslutskommuniké for Cline Scientific AB (publ), 556867-8238, for the period 1 January - 31 December 2023 | 1 | Cision News | ||
| 13.02. | Cline Scientific advisor discusses the future of cartilage damage treatment | 1 | Cision News | ||
| 18.01. | Cline Scientific provides an update on the company's financial position | 1 | Cision News | ||
| 21.11.23 | Cline Scientific's CEO convicted of market manipulation | 1 | Cision News | ||
| 21.11.23 | Judgment in the market manipulation case against Cline Scientific's CEO Patrik Sundh | 1 | Cision News | ||
| 21.08.23 | Nasdaq Stockholm AB: The observation status for Cline Scientific AB is removed (437/23) | 331 | GlobeNewswire | On May 22, 2023, Cline Scientific AB (the "Company") received observation
status with reference to material adverse uncertainty in respect of the
issuer's financial position.
On August 2, 2023, the... ► Artikel lesen | |
| 16.08.23 | Nasdaq Stockholm AB: Last day of trading in paid subscription shares (BTA B) of Cline Scientific AB (432/23) | 321 | GlobeNewswire | Trading in Cline Scientific AB paid subscription shares is to cease. The last
trading day is August 17, 2023.
Short name: CLINE BTA B
ISIN code: SE0020539245
Orderbook ID: 299313
This information... ► Artikel lesen | |
| 31.07.23 | Nasdaq Stockholm AB: Listing of paid subscription shares of Cline Scientific AB (405/23) | 280 | GlobeNewswire | With effect from August 01, 2023, the paid subscription shares in Cline
Scientific AB will be traded on First North Growth Market. Trading will
continue until further notice.
Instrument: Paid subscription... ► Artikel lesen | |
| 26.06.23 | Nasdaq Stockholm AB: Listing of subscription rights of Cline Scientific AB (350/23) | 299 | GlobeNewswire | With effect from June 26, 2023, the subscription rights in Cline Scientific AB
will be traded on First North Growth Market. Trading will continue up until and
including July 07, 2023.
Instrument:... ► Artikel lesen | |
| 22.05.23 | Nasdaq Stockholm AB: Cline Scientific AB receives observation status (284/23) | 458 | GlobeNewswire | Today, May 22, 2023, Cline Scientific AB (the "Company") disclosed a press
release with information that the Company cannot assure that it has working
capital for three months.
The rules of Nasdaq... ► Artikel lesen |
11 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,020 | +0,50 % | QIAGEN N.V.: QIAGEN verbessert Bioinformatik-Workflows mit neuer Sekundäranalyse-Lösung für Onkologie und Erbkrankheiten | QCI Secondary Analysis ist eine direkt in QCI Interpret integrierte, Cloud-basierte Software und ermöglicht durchsatzstarke Sekundäranalyse von klinischen Next-Generation-Sequencing-Daten // Dank der... ► Artikel lesen | |
| EVOTEC | 9,625 | +0,89 % | 3U Holding, BASF, Evotec, HelloFresh, Volkswagen - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| JANUX THERAPEUTICS | 53,18 | -13,49 % | Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights | SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary... ► Artikel lesen | |
| MORPHOSYS | 66,75 | -0,07 % | Aixtron, K+S, MorphoSys, Siemens Energy, SMA Solar, thyssenkrupp und Co. - Aktien-Positionen der Shortseller | Wer Aktien leer verkauft, das sogenannte Shortselling, muss Transparenzpflichten erfüllen. Wir werfen einen Blick auf aktuelle Shortseller-Meldungen. Geregelt sind diese in der EU-Leerverkaufsverordnung... ► Artikel lesen | |
| BIONTECH | 84,40 | -0,94 % | BioNTech Aktie: Trendwende oder Fehlsignal? | Die BioNTech-Aktie verzeichnet aktuell einen leichten Preisanstieg auf 83,25 €, was einer wöchentlichen Veränderung von 1,46 % entspricht. Obwohl die Aktie damit eine anhaltende Erholung zeigt, lässt... ► Artikel lesen | |
| Y-MABS THERAPEUTICS | 14,020 | -18,63 % | Y-mAbs Therapeutics GAAP EPS of -$0.15 in-line, revenue of $19.93M misses by $2.29M | ||
| SIGA TECHNOLOGIES | 7,590 | -27,44 % | SIGA Technologies, Inc. (SIGA) Q1 2024 Earnings Call Transcript | ||
| ARVINAS | 32,370 | -5,60 % | Arvinas Inc.: Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update | - Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study... ► Artikel lesen | |
| QUANTERIX | 15,980 | -7,95 % | Quanterix Releases Financial Results for the First Quarter of 2024 | BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 25,570 | +0,71 % | Avidity Biosciences, Inc.: Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1 | Avidity initiating global Phase 3 HARBOR study for delpacibart etedesiran this quarter
Delpacibart etedesiran data from MARINA-OLE showed reversal of disease progression in multiple functional measures... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,560 | -2,67 % | Recursion (RXRX) to Report Q1 Earnings: What's in the Cards? | ||
| C4 THERAPEUTICS | 6,470 | -4,85 % | C4 Therapeutics GAAP EPS of -$0.41 in-line, revenue of $3.04M misses by $6.24M | ||
| CULLINAN THERAPEUTICS | 28,190 | -3,92 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer | CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced the appointment... ► Artikel lesen | |
| ADMA BIOLOGICS | 6,800 | -1,59 % | ADMA Biologics, Inc.: ADMA Biologics to Report First Quarter 2024 Financial Results on May 9, 2024 | ||
| SUMMIT THERAPEUTICS | 5,080 | -4,33 % | Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024 | MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the... ► Artikel lesen |
CLINE SCIENTIFIC AB gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
